These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 33652477)

  • 21. Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission.
    Sheffrin M; Driscoll HC; Lenze EJ; Mulsant BH; Pollock BG; Miller MD; Butters MA; Dew MA; Reynolds CF
    J Clin Psychiatry; 2009 Feb; 70(2):208-13. PubMed ID: 19210951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
    Berman RM; Marcus RN; Swanink R; McQuade RD; Carson WH; Corey-Lisle PK; Khan A
    J Clin Psychiatry; 2007 Jun; 68(6):843-53. PubMed ID: 17592907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
    Boulton DW; Balch AH; Royzman K; Patel CG; Berman RM; Mallikaarjun S; Reeves RA
    J Psychopharmacol; 2010 Apr; 24(4):537-46. PubMed ID: 18832427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality of Life and Functioning in Comorbid Posttraumatic Stress Disorder and Major Depressive Disorder After Treatment With Citalopram Monotherapy.
    Steiner AJ; Boulos N; Mirocha J; Wright SM; Collison KL; IsHak WW
    Clin Neuropharmacol; 2017; 40(1):16-23. PubMed ID: 27764051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predicting 6-week treatment response to escitalopram pharmacotherapy in late-life major depressive disorder.
    Saghafi R; Brown C; Butters MA; Cyranowski J; Dew MA; Frank E; Gildengers A; Karp JF; Lenze EJ; Lotrich F; Martire L; Mazumdar S; Miller MD; Mulsant BH; Weber E; Whyte E; Morse J; Stack J; Houck PR; Bensasi S; Reynolds CF
    Int J Geriatr Psychiatry; 2007 Nov; 22(11):1141-6. PubMed ID: 17486678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.
    Lam RW; Milev R; Rotzinger S; Andreazza AC; Blier P; Brenner C; Daskalakis ZJ; Dharsee M; Downar J; Evans KR; Farzan F; Foster JA; Frey BN; Geraci J; Giacobbe P; Feilotter HE; Hall GB; Harkness KL; Hassel S; Ismail Z; Leri F; Liotti M; MacQueen GM; McAndrews MP; Minuzzi L; Müller DJ; Parikh SV; Placenza FM; Quilty LC; Ravindran AV; Salomons TV; Soares CN; Strother SC; Turecki G; Vaccarino AL; Vila-Rodriguez F; Kennedy SH;
    BMC Psychiatry; 2016 Apr; 16():105. PubMed ID: 27084692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy.
    Nelson JC; Thase ME; Bellocchio EE; Rollin LM; Eudicone JM; McQuade RD; Marcus RN; Berman RM; Baker RA
    Int Clin Psychopharmacol; 2012 May; 27(3):125-33. PubMed ID: 22466058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation in Turkey: A Microsimulation Approach.
    Saylan M; Treur MJ; Postema R; Dilbaz N; Savas H; Heeg BM; Drost PB
    Value Health Reg Issues; 2013; 2(2):171-180. PubMed ID: 29702862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis.
    Stewart TD; Hatch A; Largay K; Sheehan JJ; Marler SV; Berman RM; Nelson JC
    J Affect Disord; 2014 Jun; 162():20-5. PubMed ID: 24766999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
    Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T
    J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quality of life and functioning of Hispanic patients with Major Depressive Disorder before and after treatment.
    López E; Steiner AJ; Manier K; Shapiro BB; Vanle B; Parisi T; Dang J; Chang T; Ganjian S; Mirocha J; Danovitch I; IsHak WW
    J Affect Disord; 2018 Jan; 225():117-122. PubMed ID: 28826087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accelerated brain aging in major depressive disorder and antidepressant treatment response: A CAN-BIND report.
    Ballester PL; Suh JS; Nogovitsyn N; Hassel S; Strother SC; Arnott SR; Minuzzi L; Sassi RB; Lam RW; Milev R; Müller DJ; Taylor VH; Kennedy SH; Frey BN;
    Neuroimage Clin; 2021; 32():102864. PubMed ID: 34710675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality of Life, Functioning, and Depressive Symptom Severity in Older Adults With Major Depressive Disorder Treated With Citalopram in the STAR*D Study.
    Steiner AJ; Recacho J; Vanle B; Dang J; Wright SM; Miller JS; Kauzor K; Reid M; Bashmi LE; Mirocha J; Danovitch I; IsHak WW
    J Clin Psychiatry; 2017 Jul; 78(7):897-903. PubMed ID: 28858443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.
    Papakostas GI; Fava M; Baer L; Swee MB; Jaeger A; Bobo WV; Shelton RC
    Am J Psychiatry; 2015 Dec; 172(12):1251-8. PubMed ID: 26085041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder.
    Simon JS; Nemeroff CB
    J Clin Psychiatry; 2005 Oct; 66(10):1216-20. PubMed ID: 16259533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies.
    Weiss C; Weiller E; Baker RA; Duffy RA; Gwin KK; Zhang P; McQuade RD
    Int Clin Psychopharmacol; 2018 Sep; 33(5):255-260. PubMed ID: 29878915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors predicting relapse in elderly patients with major depressive disorder treated with escitalopram in an outpatient setting.
    Dolberg O; Larsson Lönn S; Kvist K
    Curr Med Res Opin; 2014 Jul; 30(7):1301-7. PubMed ID: 24628498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study.
    Han C; Wang SM; Kwak KP; Won WY; Lee H; Chang CM; Tang TC; Pae CU
    J Psychiatr Res; 2015; 66-67():84-94. PubMed ID: 26013203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: a 12-week prospective open-label multicentre study.
    Pae CU; Jeon HJ; Lee BC; Seo HJ; Kim SG; Park EJ; Kim W; Kwak KP; Han C; Cho SJ; Hahn SW; Jon DI; Choi JH; Jun TY
    Int Clin Psychopharmacol; 2013 Nov; 28(6):322-9. PubMed ID: 23873293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.